title: Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
abstract: OBJECTIVE
  To define the clinicopathologic features, outcome, and prognostic indicators of myelofibrosis (MF) in Asian patients.
  
  
  METHODS
  Two hundred and seventy consecutive Chinese patients (primary MF, n = 207; post-polycythemia vera MF, n = 27; and post-essential thrombocythemia MF, n = 36) from seven regional referral hospitals were analyzed.
  
  
  RESULTS
  The median overall survival (OS) for primary MF was 66 months. Multivariate analysis showed that age >65 years (P = 0.02), platelet count <100 × 10(9)/l (P = 0.001), and leukemic transformation (P = 0.001) negatively impacted on OS. The median OS of 63 patients with secondary MF was 44 months. In primary MF, the 10-year cumulative risk of leukemic transformation was 28%. On multivariate analysis, unfavorable karyotypes significantly predicted inferior leukemia-free survival (LFS) (P = 0.03). In secondary MF, the 10-year cumulative risk of leukemic transformation was 31%. Circulating blasts ≥1% significantly predicted inferior LFS (P = 0.04). The international prognostic scoring system (IPSS) and dynamic IPSS were not significant survival predictors in our cohort. Eighteen patients underwent allogeneic hematopoietic stem cell transplantation. The median OS post-transplantation was merely 19 months.
  
  
  CONCLUSIONS
  Platelet count <100 × 10(9)/l, unfavorable karyotypes, and circulating blasts >1% were negative prognostic indicators. Conclusion Chinese MF patients were similar to Western patients in clinicopathologic features and outcome.
authors: Harinder
authors: H
authors: Gill
authors: Anskar Y H
authors: AY
authors: Leung
authors: Chi-Chung
authors: CC
authors: Chan
authors: June S M
authors: JS
authors: Lau
authors: Candia
authors: C
authors: Chan
authors: Sze-Fai
authors: SF
authors: Yip
authors: Herman
authors: H
authors: Liu
authors: Bonnie
authors: B
authors: Kho
authors: Vivien
authors: V
authors: Mak
authors: Harold K K
authors: HK
authors: Lee
authors: Shek-Ying
authors: SY
authors: Lin
authors: Chi-Kuen
authors: CK
authors: Lau
authors: Yok-Lam
authors: YL
authors: Kwong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D044466:Asian People; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D002681:China; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010976:Platelet Count; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D055728:Primary Myelofibrosis / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D016019:Survival Analysis; D013920:Thrombocythemia, Essential / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000473:pathology*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: Chinese; Essential thrombocythemia; Myelofibrosis; Polycythemia vera